Browse STC2

Summary
SymbolSTC2
Namestanniocalcin 2
Aliases STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted
Domain PF03298 Stanniocalcin family
Function

Has an anti-hypocalcemic action on calcium and phosphate homeostasis.

> Gene Ontology
 
Biological Process GO:0001666 response to hypoxia
GO:0001890 placenta development
GO:0001893 maternal placenta development
GO:0002115 store-operated calcium entry
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006979 response to oxidative stress
GO:0006986 response to unfolded protein
GO:0007565 female pregnancy
GO:0007566 embryo implantation
GO:0007584 response to nutrient
GO:0009991 response to extracellular stimulus
GO:0010817 regulation of hormone levels
GO:0010959 regulation of metal ion transport
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0031667 response to nutrient levels
GO:0032350 regulation of hormone metabolic process
GO:0033273 response to vitamin
GO:0033280 response to vitamin D
GO:0034620 cellular response to unfolded protein
GO:0034976 response to endoplasmic reticulum stress
GO:0035264 multicellular organism growth
GO:0035966 response to topologically incorrect protein
GO:0035967 cellular response to topologically incorrect protein
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0040014 regulation of multicellular organism growth
GO:0040015 negative regulation of multicellular organism growth
GO:0042445 hormone metabolic process
GO:0042446 hormone biosynthetic process
GO:0043434 response to peptide hormone
GO:0044706 multi-multicellular organism process
GO:0045926 negative regulation of growth
GO:0046697 decidualization
GO:0046885 regulation of hormone biosynthetic process
GO:0048608 reproductive structure development
GO:0048638 regulation of developmental growth
GO:0048640 negative regulation of developmental growth
GO:0051924 regulation of calcium ion transport
GO:0055074 calcium ion homeostasis
GO:0060135 maternal process involved in female pregnancy
GO:0061458 reproductive system development
GO:0070482 response to oxygen levels
GO:0070838 divalent metal ion transport
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:1901652 response to peptide
GO:2001256 regulation of store-operated calcium entry
Molecular Function GO:0005179 hormone activity
GO:0020037 heme binding
GO:0046906 tetrapyrrole binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSTC2
Namestanniocalcin 2
Aliases STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between STC2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSTC2
Namestanniocalcin 2
Aliases STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of STC2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSTC2
Namestanniocalcin 2
Aliases STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of STC2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.2390.00264
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.4180.0889
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.1070.0987
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4020.299
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3120.804
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5160.74
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3580.464
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0250.979
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.8590.34
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3360.835
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5380.501
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1210.492
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of STC2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSTC2
Namestanniocalcin 2
Aliases STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STC2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSTC2
Namestanniocalcin 2
Aliases STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STC2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STC2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSTC2
Namestanniocalcin 2
Aliases STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STC2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSTC2
Namestanniocalcin 2
Aliases STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of STC2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSTC2
Namestanniocalcin 2
Aliases STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between STC2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSTC2
Namestanniocalcin 2
Aliases STC-2; STCRP; STC-related protein; stanniocalcin-related protein; Stanniocalcin-2
Chromosomal Location5q35.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting STC2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.